iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
New Study of 3 Oral HCV Drugs: Study of 2 Abbott new oral HCV drugs ABT-450+NNRTI either ABT-072 or ABT-333
 
 
  Clinicaltrials.gov
Phase 2 studies pegINF sparing:
 
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
 
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
 
Data presented:
 
EASL: ABT-450/Ritonavir (ABT-450/r) Combined with Pegylated Interferon Alpha-2a and Ribavirin After 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-naïve Subjects: 12-Week Interim Efficacy and Safety Results - (04/04/11)
 
EASL: Genotypic and Phenotypic Characterization of NS3 Variants Selected in HCV-Infected Patients Treated with ABT-450 - (04/05/11)
 
Boosted ABT-450/r HCV Protease 3-Day Monotherapy - (04/04/11)
 
12-Week Effiacy and Safety of ABT-072 or ABT-333 with Pegylated Interferon + Ribavirin, Following 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-Naïve Subjects - (02/19/11) 		 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org